Literature DB >> 21895958

Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience.

P A Cross1, R Naik, A Patel, A G N Nayar, J D Hemming, S L H Williamson, J A Henry, R J Edmondson, K A Godfrey, K Galaal, A Kucukmetin, A D Lopes.   

Abstract

OBJECTIVE: In centres in which intra-operative frozen section (FS) analysis is not performed, 'apparent' early-stage ovarian cancer diagnosed after surgery on paraffin section may require further restaging laparotomy or adjuvant chemotherapy. Previous studies on FS analysis have reported high sensitivity, specificity and overall accuracy. The objective of this article is to present the largest published dataset on the accuracy of FS analysis over an 11-year period from a single institution.
DESIGN: Diagnostic test accuracy.
SETTING: Northern Gynaecological Oncology Centre and Department of Cellular Pathology, Gateshead, UK. POPULATION: 1439 intra-operative FS analyses performed between January 2000 and December 2010 for suspected ovarian cancer.
METHODS: Prospectively collected data on FS analysis were compared with gold standard paraffin section. MAIN OUTCOME MEASURES: Sensitivity, specificity, likelihood ratios and post-test probability.
RESULTS: The overall sensitivity and specificity of FS analysis were 91.2% and 98.6%, respectively. Positive and negative likelihood ratios were 64.7% and 0.09%, respectively. The pre-test probability of an ovarian tumour being borderline or malignant was 45.8%. When FS analysis was reported to be positive, the post-test probability increased to 98% (confidence interval, 97-99%). Conversely, when FS analysis was reported to be negative, the post-test probability decreased to 7% (confidence interval, 6-9%). The majority of false test results were either borderline tumours or of mucinous differentiation.
CONCLUSIONS: Intra-operative FS analysis has excellent diagnostic test accuracy and assists gynaecological oncologists to perform the appropriate surgery in 95% of cases, thereby preventing the morbidity of surgical staging in benign cases and the morbidity of restaging procedures or chemotherapy in early-stage malignant tumours.
© 2011 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2011 RCOG.

Entities:  

Mesh:

Year:  2011        PMID: 21895958     DOI: 10.1111/j.1471-0528.2011.03129.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  5 in total

1.  Diagnostic accuracy of frozen section analysis of borderline ovarian tumors: a meta-analysis with emphasis on misdiagnosis factors.

Authors:  Zhen Huang; Li Li; ChengCheng Li; Samuel Ngaujah; Shu Yao; Ran Chu; Lin Xie; XingSheng Yang; Xiangning Zhang; Peishu Liu; Jie Jiang; Youzhong Zhang; Baoxia Cui; Kun Song; Beihua Kong
Journal:  J Cancer       Date:  2018-07-16       Impact factor: 4.207

2.  SERS-based detection of haptoglobin in ovarian cyst fluid as a point-of-care diagnostic assay for epithelial ovarian cancer.

Authors:  Jayakumar Perumal; Aniza Puteri Mahyuddin; Ghayathri Balasundaram; Douglas Goh; Chit Yaw Fu; Agne Kazakeviciute; U S Dinish; Mahesh Choolani; Malini Olivo
Journal:  Cancer Manag Res       Date:  2019-01-31       Impact factor: 3.989

Review 3.  Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.

Authors:  Nithya D G Ratnavelu; Andrew P Brown; Susan Mallett; Rob J P M Scholten; Amit Patel; Christina Founta; Khadra Galaal; Paul Cross; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2016-03-01

4.  Four cases of endometrioid borderline ovarian tumour: case reports and literature review.

Authors:  Eriko Nakagawa; Kaoru Abiko; Aki Kido; Sachiko Kitamura; Ken Yamaguchi; Tsukasa Baba; Sachiko Minamiguchi; Noriomi Matsumura
Journal:  BJR Case Rep       Date:  2017-10-21

5.  Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors.

Authors:  Hung Shen; Heng-Cheng Hsu; Yi-Jou Tai; Kuan-Ting Kuo; Chia-Ying Wu; Yen-Ling Lai; Ying-Cheng Chiang; Yu-Li Chen; Wen-Fang Cheng
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.